IP Library Granted Patent US 8,268,964
Granted Patent B2
US 8,268,964 · App. 12/619,039 · Granted Sep 18, 2012

MHC peptide complexes and uses thereof in infectious diseases

Assignee: Dako Denmark A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,964
App. No.
12/619,039
Granted
Sep 18, 2012
Kind
B2
Abstract

Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

Claims (17)

1. An isolated MHC multimer comprising (a-b-P) n ,

wherein n>1,

wherein a and b together form a functional MHC protein which is bound to the peptide P, forming a MHC peptide complex,

wherein each MHC peptide complex of a MHC multimer is associated with one or more multimerization domains,

wherein in at least one MHC peptide complex, P consists of the amino acid sequence FTKEDTITV (SEQ ID NO 51130).

2. The MHC multimer according to claim 1 , wherein the MHC multimer comprises MHC class 1 molecules.

3. The MHC multimer according to claim 1 , wherein the MHC multimer comprises MHC class 2 molecules.

4. The MHC multimer according to claim 1 , wherein the MI-IC multimer comprises one or more covalently or non-covalently attached labels, and wherein said one or more labels can be selected from the group consisting of fluorescent labels, fluorophores, enzymes, radioisotopes, chemiluminescent labels, dyes, bioluminescent labels, metal particles, haptens, polymers, and antibodies.

5. The MHC multimer according to claim 1 , wherein the one or more multimerization domains can be selected from the group consisting of scaffolds, carriers, optionally substituted organic molecules, membranes, liposomes or micelles, polymers, polysaccharides, dextran moieties, IgG domains, coiled-coil polypeptide structures, DNA duplexes, nucleic acid duplexes, PNA-PNA, PNA-DNA, DNA-RNA, avidins, streptavidins, antibodies, small organic molecules, proteins, cells, cell-like structures, solid support, molecules, biological polymers, and self-assembling multimeric structures.

6. The MHC multimer according to claim 1 , wherein the one or more multimerization domains comprises one or more biological cells.

7. The MHC multimer according to claim 1 , wherein the MHC multimer comprises both MHC class 1 and MHC class 2 molecules.

8. A composition comprising a plurality of MHC multimers according to claim 1 and a carrier, wherein the MHC multimers are identical.

9. A composition comprising a plurality of MHC multimers according to claim 1 and a carrier, wherein the MHC multimers are different.

10. A kit comprising a MHC multimer according to claim 1 , a positive control, and/or instructions for use.

11. A kit comprising a composition according to claim 8 , a positive control, and/or instructions for use.

12. A kit comprising a composition according to claim 9 , a positive control, and/or instructions for use.

13. A vaccine reagent comprising a MI-IC multimer according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2020
From: DAKO DENMARK APS
To: AGILENT TECHNOLOGIES, INC.
Reel/Frame 051629/0162 →
CHANGE OF NAME Recorded Jan 27, 2020
From: DAKO DENMARK A/S
To: DAKO DENMARK APS
Reel/Frame 051708/0767 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2010
From: SCHOLLER, JORGEN; PEDERSEN, HENRIK; BRIX, LISELOTTE
To: DAKO DENMARK A/S
Reel/Frame 024404/0923 →
Priority Claims (5)
DK 2007 00461 · Mar 26, 2007 · national
DK 2007 00972 · Jul 3, 2007 · national
DK 2007 00973 · Jul 3, 2007 · national
DK 2007 00974 · Jul 3, 2007 · national
DK 2007 00975 · Jul 3, 2007 · national
Continuity (8)
Continuation 12567126 · Sep 25, 2009
Continuation PCTDK2008000118 · Mar 26, 2008
Provisional Application 60907217 · Mar 26, 2007
Provisional Application 60929583 · Jul 3, 2007
Provisional Application 60929581 · Jul 3, 2007
Provisional Application 60929582 · Jul 3, 2007
Provisional Application 60929586 · Jul 3, 2007
Related Publication 20100226854A1 · Sep 9, 2010